


Johnson & Johnson Symposium:

History and Future of Dermatology – Psoriasis as an example

May 6th, 2025



Johnson & Johnson

| Dermatology

Johnson & Johnson Symposium: History and Future of Dermatology – Psoriasis as an example

Dear NCDV participants,

On behalf of the scientific board, we extend our warmest welcome to the upcoming Johnson & Johnson event. We are delighted to have such distinguished professionals joining us for this gathering. We look forward to a fruitful and engaging event in beautiful springtime Helsinki.

Best regards,

The Scientific Board

Time: May 6th, 2025

Location: Restaurant Pörssi, Fabianinkatu 14, Helsinki

Scientific Committee

Veli-Matti Kähäri, Professor of Dermatology, University of Turku & Turku University Hospital, Finland
Kaisa Tasanen-Määttä, Professor of Dermatology, University of Oulu & Oulu University Hospital, Finland
Tea Salmi, Professor of Dermatology, Tampere University & Tampere University Hospital, Finland

Learning objectives:

1. To receive an update on the most recent proceedings in inflammatory skin disease with a focus on psoriasis and psoriatic arthritis
2. To learn more on the role of IL-23 in the pathophysiology of psoriasis

Agenda

- 17.00–17.30 **Registration and coffee**
- 17.30–17.40 **Welcome and opening remarks, chairman**
Veli-Matti Kähäri, Professor of Dermatology, University of Turku & Turku University Hospital, Finland
- 17.40–17.55 **Johnson & Johnson legacy in Immunology**
Ville Pulkkinen, Medical Advisor, Johnson & Johnson Finland
- 17.55–18.40 **History of dermatology - psoriasis treatment as an example**
Mona Ståhle, Professor of Dermatology and Veneorology, Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden
- 18.40–19.15 **Future of dermatology/psoriasis treatment**
Christopher Griffiths, Emeritus Professor of Dermatology, University of Manchester, UK
- 19.15–19.30 **Closing remarks**
Veli-Matti Kähäri, Professor of Dermatology, University of Turku & Turku University Hospital, Finland
- 19.30–21.30 **Dinner**

Participants can sign up for the event when registering for the NCDV 2025. Registration will remain open until April 18th, 2025. Additionally, a confirmation e-mail will be sent from NCDV two weeks prior to the event, which must be acknowledged to secure your registration. This process has been implemented to ensure that all registered participants attend the event, and to guarantee that sufficient space is available for everyone. Participation is free of charge.

At Janssen, we have recently transitioned to the usage of our parent company's name, Johnson & Johnson, starting from the beginning of May. With over 30 years of being known as Janssen or Janssen-Cilag Oy, we have always taken pride in being a part of the Johnson & Johnson family of companies. Our goal now is to consolidate our expertise in the pharmaceutical and healthcare technology sectors under the unified brand name of Johnson & Johnson. However, the process of updating our logos, product packaging, and documentation will require a significant amount of time, so you may still come across the names and logos of Janssen-Cilag/Janssen in certain contexts.

In regard to privacy, Janssen-Cilag Oy places great importance on safeguarding your personal information and wants to ensure that you are aware of how we collect, use, and disclose such information. We will handle your information in accordance with our privacy policy as detailed in the privacy statement, as we aim to effectively manage our professional relationship with you.

Johnson & Johnson

Janssen-Cilag Oy, a Johnson & Johnson company

PL 15, 02621 ESPOO, puh. +358 20 7531 300, jacfi@its.jnj.com